As of June 4, 2025, Pharnext SA (ALPHA.PA) reports a Net Margin of -6865339.00%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Pharnext SA's Net Margin
Over recent years, Pharnext SA's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2022-12-31 | -6865339.00% |
| 2021-12-31 | -36109.97% |
| 2020-12-31 | -54140.25% |
| 2019-12-31 | -9221.49% |
| 2018-12-31 | -793.39% |
This gradual decrease highlights how Pharnext SA manages its overall profitability and cost control over time.
Comparing Pharnext SA's Net Margin to Peers
To better understand Pharnext SA's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Pharnext SA (ALPHA.PA) | -6865339.00% |
| Addex Therapeutics Ltd (ADXN.SW) | 1720.76% |
| Circassia Group PLC (CIR.L) | 12.90% |
| Synthaverse SA (BML.WA) | 12.07% |
| Biosearch SA (BIO.MC) | 5.95% |
| Biofrontera AG (B8F.DE) | -1.14% |
Compared to its competitors, Pharnext SA's Net Margin is lower than all peers, which may indicate challenges in controlling expenses or competitive pricing pressures.